Table 5 Follow-up of CXCR4 and CCR5 expression in CD4+ T lymphocytes
From: In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4
CD4+ T lymphocytes | Median (interquartile range) | Comparison by Anova | |||
|---|---|---|---|---|---|
| Â | Day 0 | Day 7 | Day 30 | Day 45 | |
% CXCR4+ cells | Â | Â | |||
Controls without statins (n = 7) | 56.2 (22.1 - 66.9) | 45.2 (22.9 - 69.5) | 68.4 (55.5 - 82.5) | 69.2 (61.2 - 97.3) | NS |
Lovastatin (n = 10) | 54.5 (34.3 - 65.5) | 30.9 (6.3 - 43.4) | 66.1 (31.0 - 76.2) | 63.8 (26.6 - 77.9) | NS |
Atorvastatin (n = 9) | 45.6 (35.6 - 64.4) | 37.1 (24.8 - 44.6) | 67.9 (51.0 - 75.6) | 18.6 (7.1 - 66.9) | NS |
MFI CXCR4 in CXCR4+ cells | Â | Â | |||
Controls without statins (n = 7) | 19.9 (6.6 - 29.1) | 15.8 (6.6 - 34.8) | 25.1 (19.8 - 43.9) | 21.2 (16.7 - 29.3) | NS |
Lovastatin (n = 10) | 16.5 (10.1 - 23.1) | 8.9 (3.7 - 11.2) | 16.3 (8.9 - 26.6) | 20.4 (7.2 - 39.0) | NS |
Atorvastatin (n = 9) | 14.1 (10.8 - 27.3) | 11.7 (7.8 - 13.2) | 23.1 (15.1 - 29.3) | 11.8 (4.3 - 33.8) | NS |
% CCR5+ cells | Â | Â | |||
Controls without statins (n = 7) | 17.4 (10.9 - 26.9) | 28.2 (7.9 - 52.75) | 35.0 (26.8 - 56.7) | 21.6 (17.6 - 25.9) | NS |
Lovastatin (n = 10) | 13.3 (6.1 - 19.7) | 9.4 (6.5 - 14.1) | 14.1 (5.1 - 21.3) | 18.1 (9.5 - 54.9) | NS |
Atorvastatin (n = 9) | 10.4 (7.6 - 18.7) | 11.1 (7.1 - 12.0) £ | 13.5 (9.3 - 18.4) | 71.4 (17.1 - 90.1) £ | £ p < 0.05 |
MFI CCR5 in CCR5+ cells | Â | Â | |||
Controls without statins (n = 7) | 8.8 (5.8 - 10.6) | 13.2 (11.1 - 19.4) | 11.1 (9.6 - 17.1) | 25.1 (13.1 - 29.1) | NS |
Lovastatin (n = 10) | 23.0 (18.9 - 29.4) | 21.9 (20.1 - 24.6) | 29.4 (19.8 - 33.4) | 24.1 (18.3 - 33.0) | NS |
Atorvastatin (n = 9) | 25.9 (20.4 - 50.2) | 21.9 (20.0 - 25.4) | 36.0 (27.0 - 42.4) | 25.1 (23.4 - 39.6) | NS |